Abstract:
A dysphagia treatment device includes: a current application unit configured to be attached to a target portion of a treated person in order to percutaneously apply current to a biological tissue of the neck including superior laryngeal nerve of the treated person; a control unit configured to control the current application unit such that percutaneous stimulation caused by an interference wave or a pseudo interference wave is applied to the biological tissue of the neck including the superior laryngeal nerve; an operation unit configured to adjust the current to be applied by the current application unit, to a sensory threshold at which the treated person becomes aware of the percutaneous stimulation; and a display unit configured to display index information based on the sensory threshold.
Abstract:
A swallowing estimation device includes: a sound detection part configured to detect sound of a larynx portion; a respiration detection part configured to detect respiration; and a swallowing estimation part configured to estimate swallowing based on sound information outputted from the sound detection part and based on respiration information outputted from the respiration detection part. The swallowing estimation part obtains a value of a parameter for swallowing estimation with respect to a biological sound generation interval that corresponds to a respiratory cessation interval longer than or equal to 400 msec, and estimates whether swallowing has occurred in the biological sound generation interval based on whether the obtained value of the parameter satisfies a swallowing determination condition.
Abstract:
A swallowing estimation device includes: a sound detection part configured to detect sound of a larynx portion; a respiration detection part configured to detect respiration; and a swallowing estimation part configured to estimate swallowing based on sound information outputted from the sound detection part and based on respiration information outputted from the respiration detection part. The swallowing estimation part obtains a value of a parameter for swallowing estimation with respect to a biological sound generation interval that corresponds to a respiratory cessation interval longer than or equal to 400 msec, and estimates whether swallowing has occurred in the biological sound generation interval based on whether the obtained value of the parameter satisfies a swallowing determination condition.
Abstract:
A multi-correction analysis method for correcting a result of analyzing a large number of object substances contained in a sample using a chromatograph, includes: grouping at least a part of a large number of object substances possibly contained in a sample to be analyzed into groups based on changes in the measured values of the part of the object substances obtained by performing chromatographic analysis of the sample under different analysis conditions, and determining a surrogate substance for each of the groups; and adding the surrogate substance to the sample as an internal standard substance common to the object substances contained in each group, and correcting a measured value of each of the large number of object substances obtained from a result of chromatographic analysis of the sample with a measured value of the internal standard substance corresponding to the group to which the object substance belongs.
Abstract:
A lipocalin-type prostaglandin D2 synthase (L-PGDS) production promoting agent, more specifically an L-PGDS production promoting agent in pericytes or ischemia-induced multipotent stem cells (iSCs) dedifferentiated from pericytes. A substance having an L-PGDS production promoting action is contained in an extract from inflamed tissues inoculated with vaccinia virus. An L-PGDS production promoting agent is highly useful as a prophylactic, therapeutic or relapse prophylactic agent for a disease in which the effect by promotion of L-PGDS expression is expected to be effective, including a cerebrovascular disorder such as cerebral infarction, dementia such as Alzheimer's disease, or a sleep disorder.
Abstract:
A diseased person distinguishing device includes a temperature pattern calculation unit that calculates a temperature pattern in an exposed region of a subject on the basis of temperature data input from a body surface temperature measurement device that measures the body surface temperature of the subject, and a subject distinguishing unit that applies a learned model that has been learned in advance to the calculated temperature pattern to determine whether the subject is a diseased person or a healthy person.
Abstract:
A swallowing diagnosis apparatus includes a controller which enables a first swallowing determination process of determining whether or not there is an aspiration risk in the swallowing on the basis of respiratory phases before and after a period in which swallowing has been estimated as having occurred; and a second swallowing determination process of extracting reference information including at least one of the sound information and the respiration information in a predetermined period including the period in which swallowing has been estimated as having occurred, obtaining a feature quantity from the extracted reference information, and performing a machine learning process on the obtained feature quantity to determine whether or not there is a possibility of dysphagia in the swallowing; and a display control process of causing a determination result obtained by the first swallowing determination process and a determination result obtained by the second swallowing determination process to be displayed.
Abstract:
The present invention provides a technique for predicting an effective patient prior to starting cancer immunotherapy. The present invention provides a method of using T cell receptor (TCR) diversity of a subject as an indicator of responsiveness of the subject to cancer immunotherapy. The present invention also provides a composition for treating cancer in a subject with high TCR diversity of T cells, comprising an immune checkpoint inhibitor. The present invention is also directed to a companion medicament using such TCR diversity.
Abstract:
The present invention provides a transgenic non-human mammal retaining, in a specifically expressible state, a DNA encoding IL-33 in the skin, and having one or more features selected from the group consisting of (1) spontaneous onset of dermatitis, (2) increase in the number of inflammatory cells, (3) increase in total IgE concentration, histamine concentration, cytokine concentration and/or chemokine concentration, and (4) increase in scratching time, under SPF (specific pathogen free) breeding conditions, as compared to a corresponding non-transgenic non-human mammal, and the like.
Abstract:
A cancer therapeutic agent according to an embodiment of the present invention contains, as active ingredients, IL-18 and one or more antibodies selected from the group consisting of an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-PD-L2 antibody, an anti-CTLA-4 antibody, an anti-CD25 antibody, an anti-CD33 antibody, and an anti-CD52 antibody.